MarketPulse
C

$CELC

4 articles found
4 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Celcuity With $170M Stake as Stock Soars 1,040%

Deerfield Management increased its Celcuity stake by $80.6M in Q4, bringing total position to $170.95M. Stock surged 1,040% amid FDA review of breast cancer drug gedatolisib.
CELCFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Celcuity Inc.

Celcuity's Gedatolisib Shows 76% Risk Reduction in Breast Cancer Trial

Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.
CELCPhase 3 trialprogression-free survival
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Celcuity as Stock Ascends 700% YoY

Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.
CELCFDA approvalbiotech
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying